MAP kinase signalling and improved Toxoplasma peptide immunogenicity regarding human toxoplasmosis

Ligia Alejandra Delatorre Cifuentes, Nestor Cardona, Laura Taborda, Juan Carlos Sepulveda-Arias, Manuel Elkin Patarroyo, Rima McLeod, Jorge Enrique Gomez-Marin

Research output: Contribution to journalResearch Articlepeer-review


Our group has already reported the effect of SAG1- and ROP18-derived peptides
on CD4+ and CD8+ T-cell proliferative responses and IFN-γ and IL-10 production
during human T. gondii infections. Although these peptides did not induce high
IFN-γ levels, SAG1 peptide 2017 from Type II T. gondii showed an immunemodulating
effect: These peptides changed cytokine profiles in ex-vivo experiments
involving peripheral blood mononuclear leukocytes from congenitally infected
children. We have determined herein whether MAP kinases were involved in such
immunomodulation and identified additional ROP 18 and SAG1 peptide sequences
that could bind to HLA molecules using bioinformatics predictions. It was found that
the SAG1 2017 II peptide significantly increased phosphorylated JNK compared to
ERK protein levels. It was determined that two new peptides, TLSSLIPEA (SAG1
protein) and GIWDYLHFA (ROP18 protein) induced higher IFN-γ levels than
empirically selected peptides, demonstrating the utility of the bioinformatics
prediction in identification of additional immunogenic peptides
Translated title of the contributionSeñalización de MAP quinasa y inmunogenicidad mejorada del péptido Toxoplasma con respecto a la toxoplasmosis humana
Original languageEnglish
Pages (from-to)1-29
Number of pages29
JournalClinical and Experimental Immunology
StatePublished - Dec 10 2014


Dive into the research topics of 'MAP kinase signalling and improved Toxoplasma peptide immunogenicity regarding human toxoplasmosis'. Together they form a unique fingerprint.

Cite this